Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

27.57 -0.57 (-2.01%)
Streaming Delayed Price Updated: 10:09 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Via ACCESS Newswire
Moderna to Host Investor Event - Analyst Day
Via ACCESS Newswire
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Via ACCESS Newswire
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
Via ACCESS Newswire
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Via ACCESS Newswire
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Via ACCESS Newswire
Moderna Announces Update on Investigational Pandemic Influenza Program
Via ACCESS Newswire
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
Via ACCESS Newswire
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
Via ACCESS Newswire
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Via ACCESS Newswire
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Via ACCESS Newswire
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Via ACCESS Newswire
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Via ACCESS Newswire
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Via ACCESS Newswire
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
Moderna to Present at Upcoming Conferences in September 2025
Via ACCESS Newswire
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Via ACCESS Newswire
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
Moderna Announces Data to be Presented at ESMO Congress 2025
Via ACCESS Newswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
Via ACCESS Newswire
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Via ACCESS Newswire
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
Via ACCESS Newswire
Moderna to Present at Upcoming Conferences in June 2025
Via ACCESS Newswire
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
Via ACCESS Newswire
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
Via ACCESS Newswire
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.